BACKGROUND: Statin therapy is beneficial for ischemic stroke patients, but little is known about whether statin adherence affects clinical outcome. We therefore evaluated the effect of statin adherence in patients with ischemic stroke or transient ischemic attack (TIA). METHODS AND RESULTS: From Taiwan Bureau of National Health Insurance database, we enrolled patients with no prior statin therapy admitted for ischemic stroke or TIA between January 2002 and December 2005. Patients were grouped based on statin adherence according to medication possession ratio (MPR): good adherence (MPR >80%; n=2,274), intermittent adherence (MPR=40-80%; n=3,710), and poor adherence (MPR <40%; n=9,424). The study endpoint was the composite outcome of recurrent ischemic stroke, hemorrhagic stroke, and acute coronary event 1 year after statin initiation. Follow-up data were obtained through December 2010. During follow-up, composite endpoints occurred in 5,354 patients (34.7%): good adherence, 798 patients (35.1%); intermittent adherence, 1,338 patients (36.1%); and poor adherence, 3,218 patients (34.1%). Compared with the good adherence group, patients in the poor adherence group and intermittent adherence group had higher risk of worse clinical outcome (adjusted HR, 1.26 and 1.16, respectively; 95% CI: 1.17-1.37 and 1.07-1.27, respectively). CONCLUSIONS: Good statin adherence was associated with better clinical outcome in patients with acute ischemic stroke or TIA. (Circ J 2016; 80: 731-737).
BACKGROUND: Statin therapy is beneficial for ischemic strokepatients, but little is known about whether statin adherence affects clinical outcome. We therefore evaluated the effect of statin adherence in patients with ischemic stroke or transient ischemic attack (TIA). METHODS AND RESULTS: From Taiwan Bureau of National Health Insurance database, we enrolled patients with no prior statin therapy admitted for ischemic stroke or TIA between January 2002 and December 2005. Patients were grouped based on statin adherence according to medication possession ratio (MPR): good adherence (MPR >80%; n=2,274), intermittent adherence (MPR=40-80%; n=3,710), and poor adherence (MPR <40%; n=9,424). The study endpoint was the composite outcome of recurrent ischemic stroke, hemorrhagic stroke, and acute coronary event 1 year after statin initiation. Follow-up data were obtained through December 2010. During follow-up, composite endpoints occurred in 5,354 patients (34.7%): good adherence, 798 patients (35.1%); intermittent adherence, 1,338 patients (36.1%); and poor adherence, 3,218 patients (34.1%). Compared with the good adherence group, patients in the poor adherence group and intermittent adherence group had higher risk of worse clinical outcome (adjusted HR, 1.26 and 1.16, respectively; 95% CI: 1.17-1.37 and 1.07-1.27, respectively). CONCLUSIONS: Good statin adherence was associated with better clinical outcome in patients with acute ischemic stroke or TIA. (Circ J 2016; 80: 731-737).
Authors: Martin Wawruch; Dusan Zatko; Gejza Wimmer; Jan Luha; Sona Wimmerova; Petra Matalova; Peter Kukumberg; Jan Murin; Tomas Tesar; Beata Havelkova; Rashmi Shah Journal: Clin Drug Investig Date: 2017-11 Impact factor: 2.859
Authors: Cecilia Dahlgren; Lukas Geary; Jan Hasselström; Clas Rehnberg; Karin Schenck-Gustafsson; Per Wändell; Mia von Euler Journal: BMJ Open Date: 2017-09-21 Impact factor: 2.692
Authors: Ye Sel Kim; Moo-Seok Park; Jun-Hwa Lee; Jong-Won Chung; Mi Ji Lee; Chi Kyung Kim; Jin-Man Jung; Kyungmi Oh; Oh Young Bang; Geong-Moon Kim; Ji-Mi Choi; Juneyoung Lee; Chin Sang Chung; Kwang Ho Lee; Woo-Keun Seo Journal: Front Neurol Date: 2018-04-24 Impact factor: 4.003